The dissociation of 80S ribosomes after termination is promoted by translation initiation factors eIF1, eIF1A, and the eIF3 complex (Pisarev et al., 2007) . In light of this, the second observation by Bolger et al. implicating Gle1 in the initiation step of translation is particularly exciting. Bolger and colleagues link Gle1 with two subunits of the eIF3 complex: Gle1 has genetic interactions with Nip1 (eIF3c) and physically associates with Prt1 (eIF3b). Furthermore, cells lacking functional Gle1 accumulate 80S monosomes, indicative of a defect in translation initiation. Although cells lacking Dbp5 also exhibit accumulation of 80S monosomes (Gross et al., 2007) , there is no evidence yet for a genetic or physical interaction of Dbp5 with the translation initiation machinery. Moreover, the IP 6 pathway was not found to be required for initiation, suggesting that Gle1/IP 6 -dependent activation of Dbp5 is not the mechanism underlying Gle1's role in initiation. Rather, the authors put forward the attractive model that Gle1 could contribute to ribosomal subunit recycling in conjunction with eIF3, thereby helping to couple translation termination to the next round of initiation. Alternatively, Gle1 might influence initiation independently of its role in termination. More biochemical experiments will be required to clarify the role of Gle1, and potentially Dbp5, in translation initiation.
The new roles for Gle1 may have implications for understanding human diseases caused by mutations in human GLE1 (hGLE1). A recent study reported that heritable mutations in hGLE1 are the cause of lethal congenital contracture syndrome type 1 (LCCS1), a fetal motor neuron disease associated with prenatal death. Two related disorders, LCCS2 and LCCS3, have also been analyzed, and those mutations map to factors acting in the phosphatidyl inositol pathway (Nousiainen et al., 2008 , and references therein). The new findings by Bolger et al. implicating Gle1 and IP 6 in mRNA export and translation beg the question of whether these syndromes could be due to defects in translation or mRNA export. Future functional analysis of the inherited mutations in these diseases could provide valuable insights into the molecular defects underlying human pathology caused by mutations in GLE1.
With the discovery that RNA interference (RNAi) occurs in mammalian cells (Elbashir et al., 2001) , it immediately became clear that RNAi is not only a powerful tool for basic research but also may represent a new therapeutic approach against viral infections and cancer. Numerous studies have established the proof of concept that diseases can be targeted by therapeutic RNAi, and several small interfering RNAs (siRNAs) are currently being tested in clinical trials (Grimm and Kay, 2007) . Despite these rapid advances, significant hurdles still need to be overcome for the widespread therapeutic application of siRNAs. Perhaps the greatest challenge is the delivery of effective quantities of siRNAs into the cytoplasm of relevant target cells in vivo (Dykxhoorn and Lieberman, 2006) . There are additional challenges for using siRNAs in the treatment of HIV-1 infection, including validating the approach in a relevant animal model and preventing the emergence of variants resistant to treatment because of the high sequence diversity of the virus. In this issue, Kumar et al. (2008) It has been shown previously that antibodies can be used to deliver siRNAs into the cytoplasm of specific target cells (Song et al., 2005) . This approach decreases the amount of siRNA that is needed, thereby minimizing the risk of undesired effects in bystander cells. In their new work, Kumar et al. use a single-chain antibody to the CD7 receptor conjugated to a nonamer arginine peptide (9R) (Figure 1 ). The CD7-specific antibody is well suited for siRNA delivery because CD7 is expressed by most T cells and is rapidly internalized. Moreover, this antibody has already been used in clinical studies to target toxins to T cell lymphomas and leukemias. In previous work, Kumar et al. (2007) demonstrated that the positively charged 9R peptide binds to polyanionic nucleic acids and can be used to deliver siRNA to neuronal cells. They now show that these techniques can be used to suppress HIV-1 replication and prevent CD4 + T cell depletion in vivo in a humanized mouse model of acquired immune deficiency syndrome (AIDS). This is a significant advance, not only because these findings enhance the prospect of a new HIV-1/AIDS therapy but also because this study introduces an siRNA delivery system that could be adapted to target different receptors and hence other cell types. Moreover, given that the binding of the siRNA to the 9R tag is noncovalent, this approach should make it possible to easily compare the efficacy of different siRNAs.
The authors demonstrate that siRNAs protect immunodeficient mice transplanted with human peripheral blood leukocytes (the Hu-PBL mouse model) from challenge with cloned HIV-1. They also show that siRNAs can suppress virus replication in mice reconstituted with peripheral blood mononuclear cells ) engrafted with human peripheral blood mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs) are injected with the CD7 antibody in complex with short interfering RNAs (scFvCD7-9R/siRNA). The siRNAs bind to the CD7 antibody through a polybasic peptide tag (nine arginines, 9R) added to the antibody. This complex delivers the siRNAs into T cells by receptor-mediated endocytosis. Some siRNAs escape the endosomal compartment and associate with the RNA-induced silencing complex (RISC). Subsequently, one RNA strand is cleaved, and the remaining one guides the activated RISC complex to the complementary mRNA. As a result of this interaction, the mRNA is cleaved, and synthesis of the respective protein is disrupted. To inhibit HIV-1 infection, Kumar et al. (2008) used a combination of siRNAs targeting CCR5, the cellular coreceptor for HIV-1, and the viral proteins Tat and Vif. CCR5 is required for HIV-1 virion fusion, the transactivator Tat is needed for effective viral transcription, and Vif promotes infectivity by degrading the host factor APOBEC3G. If not degraded, APOBEC proteins are encapsidated into budding virions and cause hypermutation of the viral genome. Thus, this siRNA cocktail inhibits HIV-1 entry into the target cell, impairs the transcription of the proviral genome, and leads to the production of viral particles with reduced infectivity. Furthermore, siRNA treatment also leads to the degradation of genomic viral RNA. plete hematopoietic system (Berges et al., 2006; Shultz et al., 2007) in which the majority of T cells show a resting phenotype. Remarkably, virus replication was markedly suppressed in these mice (chronically infected with HIV) after treatment with the siRNAs. Although the effects were less striking than those observed in the Hu-PBL mice, the improvement is notable considering that resting T cells are usually refractory to nucleic acid uptake.
Given that siRNAs usually reduce but do not entirely block protein expression, the observed levels of protection against HIV-1 infection are quite impressive. This was achieved with a combination of siRNAs targeting the cellular CCR5 coreceptor and the viral proteins Tat and Vif. CCR5 is a chemokine receptor that is essential for the fusion between the viral and host cell membranes but can be silenced without toxicity. Tat is required for effective transcription of the proviral genome, whereas Vif mediates the degradation of the cellular cytidine deaminase APOBEC3G. If it is not degraded, APOBEC3G is incorporated into progeny virions, leading to lethal hypermutations in the viral genome upon infection of a new target cell. Thus, this combination siRNA therapy targets early, intermediate, and late steps of the virus life cycle. Similar to standard antiretroviral therapy, a combination of siRNAs appears to be essential to prevent the emergence of HIV-1 variants that escape treatment, because treatment with an siRNA targeting CCR5 alone was less effective than a combination of siRNAs in suppressing viral replication.
Notably, this study did not find evidence of immunological toxicity, nonspecific immune activation, or alterations in microRNA levels. Nevertheless, many parameters need to be optimized before this approach can be used in a clinical setting. For example, the efficiency of siRNA delivery must be improved, and additional antibodies need to be developed to target macrophages and dendritic cells that are also infected by HIV-1. A more difficult challenge will be to keep concentrations of siRNA within an effective range for several years during chronic HIV-1 infection, especially given that administration of siRNAs by intravenous injection every few days would be extremely expensive and logistically arduous. Although improved delivery systems are currently being developed (Akhtar and Benter, 2007) and chemical modifications may increase the stability, pharmacokinetics, and potency of siRNAs (Corey, 2007) , additional technical breakthroughs are necessary before widespread clinical application would be possible. Vectormediated delivery of short hairpin RNAs (shRNAs) to hematopoietic stem cells is an alternative approach, but it has proven difficult to achieve and to maintain the expression of effective levels of shRNAs in vivo. Furthermore, it is very likely that HIV-1 escape variants will emerge during long-term treatment. This is not a crucial problem if one can rapidly switch to different siRNAs (as in the current study) but constitutes a major hurdle for approaches that rely on stable RNAi expression.
To date, more than 20 drugs against HIV/AIDS have been approved for clinical use. Most of them are highly effective and can be administered orally. Because siRNA-based drugs are currently expensive and difficult to administer, it is unlikely that they will soon become a viable alternative to antiretroviral therapy or a treatment option for AIDS in developing countries. However, they may be useful for the treatment of individuals harboring HIV-1 variants resistant to existing drug regimens. Clearly, long-term silencing of a virus that is highly variable, infects various cell types, and persists for life is an extremely challenging task. However, there is also an urgent need for drugs against acute viral infections causing respiratory diseases, encephalitis, and hemorrhagic fever. The results of Kumar et al. show that the potency of silencing by siRNAs can be combined with the specificity of an antibody to deliver effective quantities of siRNAs into a specific cell type in vivo. In principle, antibodies could be directed against any surface protein and the addition of polybasic peptide tags to an antibody should allow the conjugation of any siRNA. It is this potential versatility that raises the hope that new siRNA-based drugs will one day be created to counter the numerous viral infections that currently cannot be treated.
